These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 31328873)
1. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy. Tao X; Zhang H; Yang Y; Zhang C; Wang M Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873 [TBL] [Abstract][Full Text] [Related]
2. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640 [TBL] [Abstract][Full Text] [Related]
3. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model. Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935 [TBL] [Abstract][Full Text] [Related]
4. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270 [TBL] [Abstract][Full Text] [Related]
5. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders. Sherman RA Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681 [TBL] [Abstract][Full Text] [Related]
6. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients. Bertonsello-Catto VR; Lucca LJ; da Costa JAC Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281 [TBL] [Abstract][Full Text] [Related]
7. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis. Hung KY; Liao SC; Chen TH; Chao MC; Chen JB Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497 [TBL] [Abstract][Full Text] [Related]
8. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia. Cupisti A; D'Alessandro C; Baldi R; Barsotti G J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782 [TBL] [Abstract][Full Text] [Related]
9. Interventional study to improve adherence to phosphate binder treatment in dialysis patients. Hjemås BJ; Bøvre K; Mathiesen L; Lindstrøm JC; Bjerknes K BMC Nephrol; 2019 May; 20(1):178. PubMed ID: 31101020 [TBL] [Abstract][Full Text] [Related]
10. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial. Yin J; Yin J; Lian R; Li P; Zheng J BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293 [TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients. Chan MW; Cheah HM; Mohd Padzil MB Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884 [TBL] [Abstract][Full Text] [Related]
12. The adequacy of phosphorus binder prescriptions among American hemodialysis patients. Huml AM; Sullivan CM; Leon JB; Sehgal AR Ren Fail; 2012; 34(10):1258-63. PubMed ID: 23013171 [TBL] [Abstract][Full Text] [Related]
13. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis. Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076 [TBL] [Abstract][Full Text] [Related]
14. Phosphates in medications: Impact on dialysis patients . Sawin DA; Ma L; Stennett A; Ofsthun N; Himmele R; Kossmann RJ; Maddux FW Clin Nephrol; 2020 Apr; 93(4):163-171. PubMed ID: 32049627 [TBL] [Abstract][Full Text] [Related]
15. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627 [TBL] [Abstract][Full Text] [Related]
16. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE; Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079 [TBL] [Abstract][Full Text] [Related]
17. Adherence and knowledge about hyperphosphatemia treatment in hemodialysis patients with hyperphosphatemia. Nerbass FB; Morais JG; dos Santos RG; Krüger TS; Koene TT; da Luz Filho HA J Bras Nefrol; 2010; 32(2):149-55. PubMed ID: 21103674 [TBL] [Abstract][Full Text] [Related]